Recruiting NCT05705778

Plasma Biomarker in Amblyopia Patients

— Observational Amblyopia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: The protocol lists: standard amblyopia treatment.
Who it may be relevant to: Registry conditions: Amblyopia. Basic parameters: 3 years — 12 years · All.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: China
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Prognostic Value of Plasma Biomarkers Among Patients With Amblyopia

Overview

This prospective study aims to observe the predictive effect of peripheral blood plasma biomarker on the outcome of treatment in children with different types of amblyopia. We also investigated the mechanism of neuromodulation in the visual development of amblyopic children.

Interventions

Procedure standard amblyopia treatment
amblyopia treatment following international guidelines and genetic tests.

Primary outcome measures

Plasma protein predictor screening for visual acuity improvement following amblyopia therapy using Tandem Mass Tags proteomics [Time frame: 2 years after including into this clinical trial]

Eligibility criteria

Inclusion criteria

Diagnosed with amblyopia
3-12 years of age
Able to tolerate amblyopia treatment
Agree to be involved in this study and agree to have a follow up visit every 3 months.

Exclusion criteria

Have previous treatment history before
Have pathological ocular anomalies known to cause reduced visual acuity
Have previous psychiatric, visual or neurological disorders
Have eccentric fixation and/or abnormal retinal correspondence
Have attention disorder and learning disability that cannot comprehend psychophysical test instructions given and/or consent for themselves

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model: Cohort

Study locations

China · 1 center

Zhongshan Ophthalmic Center — Guangzhou

Identifiers

NCT: NCT05705778 · 2022KYPJ102

Primary sources (government registries)

ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗